€91.75
0.03% day before yesterday
Paris, Dec 24, 02:00 pm CET
ISIN
FR0000120578
Symbol
SAN
Sector
Industry

Sanofi Stock price

€91.75
-1.04 1.12% 1M
+0.88 0.97% 6M
+1.99 2.22% YTD
+2.41 2.70% 1Y
+3.70 4.20% 3Y
+1.65 1.83% 5Y
+17.20 23.07% 10Y
Paris, Closing price Wed, Dec 25 2024
+0.00 0.00%
ISIN
FR0000120578
Symbol
SAN
Sector
Industry

Key metrics

Market capitalization €114.48b
Enterprise Value €131.75b
P/E (TTM) P/E ratio 27.21
EV/FCF (TTM) EV/FCF 24.21
EV/Sales (TTM) EV/Sales 2.99
P/S ratio (TTM) P/S ratio 2.60
P/B ratio (TTM) P/B ratio 1.58
Dividend yield 4.10%
Last dividend (FY23) €3.76
Revenue growth (TTM) Revenue growth 1.61%
Revenue (TTM) Revenue €44.09b
EBIT (operating result TTM) EBIT €9.37b
Free Cash Flow (TTM) Free Cash Flow €5.44b
EPS (TTM) EPS €3.37
P/E forward 15.19
P/S forward 2.49
EV/Sales forward 2.87
Show more

Is Sanofi a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,885 stocks worldwide.

Sanofi Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a Sanofi forecast:

17x Buy
77%
3x Hold
14%
2x Sell
9%

Analyst Opinions

22 Analysts have issued a Sanofi forecast:

Buy
77%
Hold
14%
Sell
9%

Financial data from Sanofi

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
44,092 44,092
2% 2%
100%
- Direct Costs 16,990 16,990
5% 5%
39%
27,102 27,102
1% 1%
61%
- Selling and Administrative Expenses 6,317 6,317
13% 13%
14%
- Research and Development Expense 6,958 6,958
3% 3%
16%
13,827 13,827
4% 4%
31%
- Depreciation and Amortization 4,453 4,453
28% 28%
10%
EBIT (Operating Income) EBIT 9,374 9,374
4% 4%
21%
Net Profit 4,216 4,216
51% 51%
10%

In millions EUR.

Don't miss a Thing! We will send you all news about Sanofi directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sanofi Stock News

AD HOC NEWS
2 months ago
Ein deutliches Plus bei Impfstoffen hat dem französischen Pharmakonzern Sanofi FR0000120578 ein überraschend gutes drittes Quartal beschert.
AD HOC NEWS
2 months ago
Ein deutliches Plus bei Impfstoffen hat dem französischen Pharmakonzern Sanofi FR0000120578 ein überraschend gutes drittes Quartal beschert.
AD HOC NEWS
2 months ago
Der französische Pharmakonzern Sanofi FR0000120578 hat seine Gespräche mit der Investmentgesellschaft Clayton Dubilier & Rice (CD&R) über einen Einstieg in das Geschäft mit rezeptfreien Arzneien vertieft.
More Sanofi News

Company Profile

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Head office France
CEO Paul Hudson
Employees 87,994
Founded 1994
Website www.sanofi.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today